Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

Byrd, J.; R. Brown, Jennifer; O'brien, S.; Barrientos, J.; Kay, N.; Reddy, N.; Coutre, S.; Tam, C.; Mulligan, S.; Jaeger, U.; Devereux, S.; Barr, P.; Furman, R.; Kipps, T.; Cymbalista, F.; Pocock, C.; Thornton, P.; Caligaris‐cappio, F.; Robak, T.; Delgado, J.; Schuster, S.; Montillo, M.; Schuh, A.; de Vos, S.; Gill, D.; Bloor, A.; Dearden, C.; Moreno, C.; J Jones, Jeffrey; Chu, A.; Fardis, M.; Mcgreivy, J.; Clow, F.; James, D.; Hillmen, P.

doi:10.1056/NEJMoa1400376

Public

Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

Shared by NobleBlocks on May 31, 2014 • 12:00 AM UTC

Authors:

J. Byrd

Jennifer R. Brown

S. O'brien

Abstract

Background In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton’s tyrosine kinase, ...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!